2,4-Dinitrophenol

Last updated

2,4-Dinitrophenol
2,4-Dinitrophenol.svg
2,4-Dinitrophenol.jpg
Chemical structure (top) and sample of pure compound (top)
Clinical data
Routes of
administration
Oral
Drug class Uncoupling agents
Legal status
Legal status
  • Banned for human consumption in many countries
Pharmacokinetic data
Metabolism Nitro reduction
Elimination half-life Unknown
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.080 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C6H4N2O5
Molar mass 184.107 g·mol−1
3D model (JSmol)
  • O=[N+]([O-])c1cc(ccc1O)[N+]([O-])=O
  • InChI=1S/C6H4N2O5/c9-6-2-1-4(7(10)11)3-5(6)8(12)13/h1-3,9H Yes check.svgY
  • Key:UFBJCMHMOXMLKC-UHFFFAOYSA-N Yes check.svgY

2,4-Dinitrophenol (2,4-DNP or simply DNP) is an organic compound with the formula HOC6H3(NO2)2. It has been used in explosives manufacturing and as a pesticide and herbicide.

Contents

In humans, DNP causes dose-dependent mitochondrial uncoupling, causing the rapid loss of ATP as heat and leading to uncontrolled hyperthermia—up to 44 °C (111 °F)—and death in case of overdose. Researchers noticed its effect on raising the basal metabolic rate in accidental exposure and developed it as one of the first weight loss drugs in the early twentieth century. DNP was banned from human use by the end of the 1930s due to its risk of death and toxic side effects. DNP continues to be used after its ban and experienced a resurgence in popularity after it became available on the Internet.

Chemical properties

Synthesis of DNP (right) from phenol and nitric acid via 2-Nitrophenol and 4-Nitrophenol Synthesis 2,4-Dinitrophenol.svg
Synthesis of DNP (right) from phenol and nitric acid via 2-Nitrophenol and 4-Nitrophenol

DNP has the chemical formula HOC6H3(NO2)2. As a solid, it is a yellow, crystalline and has a sweet, musty odor. [1] [2] It sublimates, is volatile with steam, and is soluble in most organic solvents as well as aqueous alkaline solutions. [2] DNP is a member of the dinitrophenols chemical family. [1]

DNP can be produced by hydrolysis of 2,4-dinitrochlorobenzene. [1] [3] Other routes of DNP synthesis include nitration of monochlorobenzene, nitration of benzene with nitrogen dioxide and mercurous nitrate, oxidation of 1,3-dinitrobenzene, [4] and nitration of phenol with nitric acid. [5]

A dust explosion is possible with DNP in powder or granular form in the presence of air. DNP may explosively decompose when submitted to shock, friction or concussion, and may explode upon heating. [6] DNP forms explosive salts with strong bases as well as ammonia, and emits toxic fumes of nitrogen dioxide when heated to decomposition. [7] DNP's explosive strength is 81% that of TNT, based on the Trauzl lead block test. [8]

Uses

Industrial

Historically, DNP has been used as an antiseptic and as a non-selective bioaccumulating pesticide. [9]

DNP was particularly useful as a herbicide alongside other closely related dinitrophenol herbicides like 2,4-dinitro-o-cresol (DNOC), dinoseb and dinoterb. [10] Since 1998 DNP has been withdrawn from agricultural use. [11] Currently, there are no actively registered pesticides containing DNP in the United States or Europe. [12] [13] Dinoseb is used industrially as a polymerisation inhibitor during styrene production. In 2023, the Home Office said it could not determine any legitimate industrial uses for DNP in the United Kingdom. [14]

It is a chemical intermediate in the production of sulfur dyes, [3] wood preservatives [9] and picric acid. [15] A precursor to 2,4,6-trinitrotoluene (TNT), DNP has also been used to make photographic developers and explosives. [16] [17] DNP is classified as an explosive in the United Kingdom [18] and the United States. [19]

In humans

Histogram of DNP doses reported on online forums and the subreddit /r/DNP Histogram of DNP (dinitrophenol) doses reported on online forums.png
Histogram of DNP doses reported on online forums and the subreddit /r/DNP

DNP raises energy expenditure by 30 to 40 percent and causes a weight loss of 0.7–0.9 kilograms (1.5–2.0 lb) per week. [21] Although DNP is no longer in clinical use as a weight loss drug due to its dangerous side effects, its mechanism of action remains under investigation as a potential approach for treating obesity and non-alcoholic fatty liver disease. [1] [22] [23] Researches developed a prodrug, HU6, which is metabolized to DNP in the liver to provide more stable blood concentrations. HU6 completed a phase II trial in which it produced significant reductions in liver fat and body weight in overweight people with elevated liver fat, without serious adverse effects. [24]

DNP is used by bodybuilders, fitness enthusiasts, and people with an eating disorder to lose weight. The user profile is similar to that of anabolic steroids; many perceive it to be effective and with manageable risks. [25] Despite health warnings from regulators, DNP is readily available online [25] sometimes under other names such as Dinosan, Dnoc, Solfo Black, Nitrophen, Aldifen, and Chemox. [17] [25] DNP is often sold in tablets containing 100 to 200 mg [1] and may be sold alongside other substances such as anabolic steroids and thyroxine. [17] It may also be found as a contaminant in other bodybuilding supplements not advertised as containing DNP. [25] Online message boards provide information on dosage and regimens for DNP use, and describe the risks of taking the compound and provide advice on how to mitigate hyperthermia. [17] [25] [26] According to a study published in 2023, the most commonly reported doses were between 150 and 300 mg/day. [20] Between 2010 and 2020, reports of overdoses were higher in Australasia, Europe and North America than in Asia, Africa, and South or Central America. [27]

It is also used as a suicide method. [17]

Biochemistry

Mechanism of action

Nitro reduction of DNP Nitro reduction of 2,4-Dinitrophenol (DNP).png
Nitro reduction of DNP

In living cells, DNP acts as a protonophore, an agent that can shuttle protons (hydrogen cations) across biological membranes. It dissipates the proton gradient across the mitochondrial membrane, collapsing the proton motive force that the cell uses to produce most of its ATP chemical energy. Instead of producing ATP, the energy of the proton gradient is lost as heat. [17] The inefficiency is proportional to the dose of DNP that is taken. As the dose increases and energy production is made more inefficient, metabolic rate increases (and more fat is burned) in order to compensate for the inefficiency and to meet energy demands. DNP is probably the best known agent for uncoupling oxidative phosphorylation. The phosphorylation of adenosine diphosphate (ADP) by ATP synthase gets disconnected or uncoupled from oxidation.[ citation needed ]

DNP raises the basal metabolic rate (BMR) and lowers T4 (thyroid hormone) levels by increasing T4 metabolism and reducing thyroid hormone secretion. Because it binds to thyroxine-binding globulin, overall thyroid function may not be affected. DNP cannot substitute for thyroid hormone in myxedema. [28]

Pharmacokinetics

Information about pharmacokinetics and pharmacodynamics of DNP in humans is limited. [23] DNP is metabolized via nitro reduction. Its major metabolites are 2-amino-4-nitrophenol  [ de ] and 4-amino-2-nitrophenol. [16] In overdoses, symptom onset can be as soon as 3 hours and the average time to death was 14 hours. [16] [17]

As a pollutant

Although many militaries are replacing traditional 2,4,6-trinitrotoluene (TNT)-based explosives for insensitive munitions, DNP is a degradation byproduct of the IMX-101 insensitive munition used by the United States Army. [29]

While the Meisenheimer charge transfer reaction is effective at detecting TNT, it is not effective at detecting many other explosives including DNP. Researchers are studying colorimetric detection and other methods for DNP to find if water or solids such as soils are contaminated with DNP. [30] [31] [32] [33] UiO-66-NH2 can be used to bind to and remove DNP from solution. [34]

Adverse effects

DNP has a low therapeutic index, meaning that the dosage required for a desired effect is not much smaller than that which produces toxicity. [17] Individual tolerance to DNP's harmful short- and long-term effects varies greatly. [1] The most common adverse effect reported is a rash, which could be maculopapular, urticarial, angioedema, or an exfoliative dermatitis. [17] Cataracts can form, causing a permanent loss of vision in days to months of usage, and permanent deafness has also been reported. [17] [35] Other adverse effects reported include peripheral neuritis, agranulocytosis, and neutropaenia. [17] Negative effects on the central nervous system, cardiovascular system, and bone marrow can occur. [1] In animal studies, DNP acted as a teratogen, mutagen, and carcinogen and caused developmental and reproductive harm. [17] An unusually yellow coloring of the skin, mucous membranes, sclera, urine, stomach contents, and internal organs is an indication of DNP exposure, but does not occur in every case. [36] Contact with skin or inhalation can cause DNP poisoning. Symptoms are typically mild with dermal exposure, but inhalation can lead to systemic effects, the same way as oral exposure. [17]

Overdose

Overdose is extremely dangerous; [17] cases reported to poison control centers had a 11.9 percent fatality rate between 2010 and 2020. [27] Although the largest number of overdose deaths occurred in the 1910s and 1920s when the chemical was in more widespread industrial use, [1] the substance's use as a dieting aid has caused a number of fatalities in the twenty-first century: [17] at least 50 overdose deaths were reported worldwide between 2010 and 2020. [27] Although the lowest published fatal ingested dose is 4.3 mg/kg, [17] [16] a typical overdose death occurs at a higher level of exposure, around 20-50 mg/kg. [1]

The first symptoms to appear are nausea, vomiting, abdominal pain, and perhaps diarrhea. [16] The typical overdose syndrome seen with DNP and other phenols is a combination of hyperthermia, tachycardia, diaphoresis, and tachypnoea. [16] [17] Because of the heat produced during uncoupling, DNP overdose will overpower the body's attempt to maintain thermal homeostasis and cause an uncontrolled, fatal rise in body temperature up to as high as 44 °C (111 °F). The disruption of metabolism also leads to the accumulation of potassium and phosphate, potentially contributing to toxicity. DNP can cause T wave and ST segment abnormalities; heart muscle, kidney, and liver damage have been found on autopsy. [16] [17] According to an analysis of United Kingdom and United States overdose cases, tachycardia, hyperpyrexia, acidosis, and agitation or confusion are independent predictors of overdose death. [37]

There is no antidote to DNP and management strategies are based on expert opinion and case studies. [17] Treatment for overdose is supportive, and often involves aggressive cooling using methods such as ice baths and intravenous fluids. [35] [17] Grundlingh et al. recommend administering activated charcoal if the patient presents within an hour of ingestion and using intravenous vasopressors or inotropes to control blood pressure if necessary. Intravenous methylthioninium chloride can treat methaemoglobinaemia. Benzodiazepines can help control seizures and dantrolene has been used in an attempt to control hyperthemia. [17] Cardiopulmonary resuscitation (CPR) has been used on people who died of DNP overdoses but has no known successful outcomes. [17]

History

During World War I, munitions workers in France fell ill and some died from DNP exposure. [38] Stanford University academic Maurice L. Tainter learned of DNP's effect in raising the metabolic rate and causing weight loss and pioneered its use as a weight loss drug. [1] [38] Although he was aware of DNP's narrow therapeutic index, Tainter tried the drugs on obese patients and published successful results in 1933; average weight loss was 20 pounds (9.1 kg) and most recipients did not report adverse effects. In 1934, Tainter estimated that at least 100,000 people had been treated with DNP in the United States during its first year on the market and there had been three reported fatalities connected to the drug. [38] [1] Tainter argued that DNP was highly effective in raising the metabolic rate (up to 50 percent) and avoided the negative circulatory effects of desiccated thyroid, another weight loss drug in use at the time. [38]

DNP explainer in the FDA publication "Chamber of Horrors" Dinitrophenol (DNP) chamber of horrors.jpg
DNP explainer in the FDA publication "Chamber of Horrors"

Other physicians were less optimistic about the adverse effects of DNP, and in 1935 the American Medical Association's Council on Chemistry and Pharmacy declined to list DNP in the New and Nonofficial Remedies on the grounds that its benefits did not exceed its risks to health. [38] Reports of cataracts forming during DNP usage administered by a physician appeared the same year; in 1936 an ophthalmologist based in San Francisco estimated that 2,500 American women had gone blind from DNP use. [38] Physician opinion turned against the drug, but many people bought direct-to-consumer preparations of DNP—marketed as a cosmetic rather than a drug to evade existing regulations. [38] [39]

DNP's risks were highlighted in the "Chamber of Horrors", an exhibit assembled by the Food and Drug Administration to explain the limitations of existing American drug regulations. In 1938, the Food, Drug, and Cosmetic Act increased the FDA's ability to regulate drugs. DNP was deemed so toxic as to be banned for human consumption and in 1940 the FDA reported that there was no evidence of continued sale for this purpose. [39] [38] Nevertheless, it continued to be used for weight loss. [35] William F. Loomis and Fritz Albert Lipmann discovered DNP's mechanism of action and reported it in a 1948 publication. [38] Reports of its use increased in the twenty-first century after the drug became available on the Internet. [35]

DNP is banned for human consumption in many countries. [1] Because it has some legitimate uses, in many jurisdictions, DNP is legal to sell not for human consumption. [25] [40] [41] In Australia, all dinitrophenols were classified as Schedule 1 dangerous drugs in 1956. In February 2017, DNP was reclassified as Schedule 10, "Substances of such a danger to health as to warrant prohibition of sale, supply and use". [40] From 1 October 2023, DNP will be classified as a regulated poison in the United Kingdom. [42] It is a prohibited substance (class F4) in Brazil. [43] In the United States, DNP is classified as an investigational new drug; it received orphan drug status for Huntington's disease. [44] DNP has been banned by the World Anti-Doping Association since 2015. [45]

Petróczi et al. recommend against campaigns informing people of the risks of DNP because it could increase use of the drug. [25] However, Sousa et al. argue that publicity campaigns in the United Kingdom in the early and mid-2010s reduced DNP usage. [1] In 2015, Interpol and the World Anti-Doping Agency released an orange notice warning of the dangers of DNP. [25]

In 1941, the Eastman Kodak Company, a bulk distributor of DNP, was investigated after some of its product was found in illegal diet pills. [39] Nicholas Bachynsky, a Texas physician, provided the drug to patients under the name "Mitcal". He was convicted of violating drug laws in 1986, but continued to work with DNP and was additionally convicted of fraud in 2008. [35] [17] In 2018, a seller in the United Kingdom was convicted of manslaughter for selling DNP for human consumption. The conviction was sent to retrial in 2020 by the English Court of Appeal, where the seller was, once again, convicted of gross negligence manslaughter. [46]

Related Research Articles

<span class="mw-page-title-main">Topiramate</span> Medication used to treat epilepsy and migraine

Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines. It has also been used in alcohol dependence and essential tremor. For epilepsy this includes treatment for generalized or focal seizures. It is taken orally.

<span class="mw-page-title-main">Anti-obesity medication</span> Class of pharmacological agents

Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body, weight regulation, by: reducing appetite and consequently energy intake, increasing energy expenditure, redirecting nutrients from adipose to lean tissue, or interfering with the absorption of calories.

<span class="mw-page-title-main">Levothyroxine</span> Thyroid hormone

Levothyroxine, also known as L-thyroxine, is a synthetic form of the thyroid hormone thyroxine (T4). It is used to treat thyroid hormone deficiency (hypothyroidism), including a severe form known as myxedema coma. It may also be used to treat and prevent certain types of thyroid tumors. It is not indicated for weight loss. Levothyroxine is taken orally (by mouth) or given by intravenous injection. Levothyroxine has a half-life of 7.5 days when taken daily, so about six weeks is required for it to reach a steady level in the blood.

Thermogenic means tending to produce heat, and the term is commonly applied to drugs which increase heat through metabolic stimulation, or to microorganisms which create heat within organic waste. Approximately all enzymatic reaction in the human body is thermogenic, which gives rise to the basal metabolic rate.

<span class="mw-page-title-main">25I-NBOMe</span> Synthetic hallucinogen

25I-NBOMe is a novel synthetic psychoactive substance with strong hallucinogenic properties, synthesized in 2003 for research purposes. Since 2010, it has circulated in the recreational drug scene, often misrepresented as LSD. The recreational usage of 25I is associated with severe intoxication and deaths in humans.

<span class="mw-page-title-main">Dinoseb</span> Chemical compound used as a herbicide

Dinoseb is a common industry name for 6-sec-butyl-2,4-dinitrophenol, a herbicide in the dinitrophenol family. It is a crystalline orange solid which does not readily dissolve in water. Dinoseb is banned as an herbicide in the European Union (EU) and the United States because of its toxicity.

<span class="mw-page-title-main">DALT</span> Chemical compound

N,N-Diallyltryptamine (DALT) is a tryptamine derivative which has been identified as a new psychoactive substance. It has been used as an intermediate in the preparation of radiolabeled diethyltryptamine.

<span class="mw-page-title-main">25C-NBOMe</span> Psychedelic drug

25C-NBOMe is a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. 25C-NBOMe appeared on online vendor sites in 2010 but was not reported in the literature until 2011. It acts as a potent agonist of the 5-HT2A receptor, and has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET). Multiple deaths have occurred from usage of 25C-NBOMe due to the ease of accidental overdose. The long-term toxic effects of the drug have not been researched.

Fish acute toxicity syndrome (FATS) is a set of common chemical and functional responses in fish resulting from a short-term, acute exposure to a lethal concentration of a toxicant, a chemical or material that can produce an unfavorable effect in a living organism. By definition, modes of action are characterized by FATS because the combination of common responses that represent each fish acute toxicity syndrome characterize an adverse biological effect. Therefore, toxicants that have the same mode of action elicit similar sets of responses in the organism and can be classified by the same fish acute toxicity syndrome.

<span class="mw-page-title-main">25D-NBOMe</span> Chemical compound

25D-NBOMe is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5-HT2A receptor. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe. It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.

<span class="mw-page-title-main">25N-NBOMe</span> Chemical compound

25N-NBOMe is a derivative of the hallucinogen 2C-N. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as 25I-NBOMe and 25C-NBOMe, which are potent agonists at the 5HT2A receptor. 25N-NBOMe has been sold as a street drug and has only been described in the literature in terms of identification by forensic analysis.

<span class="mw-page-title-main">25E-NBOMe</span> Chemical compound

25E-NBOMe is a derivative of the phenethylamine 2C-E. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5-HT2A receptor. 25E-NBOMe has been sold as a drug and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe.

<span class="mw-page-title-main">Poisoning</span> Medical condition

Poisoning is the harmful effect which occurs when toxic substances are introduced into the body. The term "poisoning" is a derivative of poison, a term describing any chemical substance that may harm or kill a living organism upon ingestion. Poisoning can be brought on by swallowing, inhaling, injecting or absorbing toxins through the skin. Toxicology is the practice and study of symptoms, mechanisms, diagnoses, and treatments correlated to poisoning.

<span class="mw-page-title-main">25G-NBOMe</span> Chemical compound

25G-NBOMe (NBOMe-2C-G) is a derivative of the phenethylamine hallucinogen 2C-G, which acts as a highly potent agonist for the human 5-HT2A receptor.

<span class="mw-page-title-main">25H-NBOMe</span> Chemical compound

25H-NBOMe (NBOMe-2C-H) is a derivative of the phenethylamine hallucinogen 2C-H, which acts as a highly potent full agonist for the human 5-HT2A receptor.

<span class="mw-page-title-main">25iP-NBOMe</span> Chemical compound

25iP-NBOMe is a derivative of the phenethylamine hallucinogen 2C-iP, which acts as a highly potent agonist for the human 5-HT2A receptor.

<span class="mw-page-title-main">25-NB</span> Family of serotonergic psychedelics

The 25-NB (25x-NBx) series, sometimes alternatively referred to as the NBOMe compounds, is a family of serotonergic psychedelics. They are substituted phenethylamines and were derived from the 2C family. They act as selective agonists of the serotonin 5-HT2A receptor. The 25-NB family is unique relative to other classes of psychedelics in that they are, generally speaking, extremely potent and relatively selective for the 5-HT2A receptor. Use of NBOMe series drugs has caused many deaths and hospitalisations since the drugs popularisation in the 2010s. This is primarily due to their high potency, unpredictable pharmacokinetics, and sellers passing off the compounds in the series as LSD.

Nicholas Bachynsky is a Russian-born American former doctor and convicted fraudster. In the 1980s, he ran a weight loss clinic in Texas where he provided the unlicensed drug 2,4-Dinitrophenol (DNP) to patients under the name "Mitcal"; court filings reported that he had treated 14,000 people with the drug. Many reported adverse effects. After one patient died of an overdose in 1984, Bachynsky was convicted and fined for violating drug laws. Despite this, he continued to dispense DNP. In 2008, he was convicted of fraud for his role in a scheme to sell DNP.

Energy expenditure, often estimated as the total daily energy expenditure (TDEE), is the amount of energy burned by the human body.

<span class="mw-page-title-main">HU6</span> Chemical compound

HU6 is a prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider therapeutic index and improve safety." Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for metabolic dysfunction-associated steatohepatitis. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly. A phase 2b trial was launched in late 2023.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 Sousa, Daniela; Carmo, Helena; Roque Bravo, Rita; Carvalho, Félix; Bastos, Maria de Lourdes; Guedes de Pinho, Paula; Dias da Silva, Diana (April 2020). "Diet aid or aid to die: an update on 2,4-dinitrophenol (2,4-DNP) use as a weight-loss product". Archives of Toxicology. 94 (4): 1071–1083. doi:10.1007/s00204-020-02675-9. PMID   32078021. S2CID   211194992.
  2. 1 2 Budavari, Susan; et al., eds. (1989). The Merck index : an encyclopedia of chemicals, drugs, and biologicals (11th ed.). Rahway, NJ: Merck. p.  1900. ISBN   978-0-911910-28-5. OCLC   21297020.
  3. 1 2 Gerald Booth "Nitro Compounds, Aromatic" in "Ullmann's Encyclopedia of Industrial Chemistry" 2007; Wiley-VCH, Weinheim. doi : 10.1002/14356007.a17_411
  4. Shea et al. 1983, p. 2.
  5. Khabarov, Yu. G.; Lakhmanov, D. E.; Kosyakov, D. S.; Ul'yanovskii, N. V. (1 October 2012). "Synthesis of 2,4-dinitrophenol". Russian Journal of Applied Chemistry. 85 (10): 1577–1580. doi:10.1134/S1070427212100163. ISSN   1608-3296. S2CID   98830371.
  6. Stellman, Jeanne Mager (1998). Encyclopaedia of Occupational Health and Safety: Guides, indexes, directory. International Labour Organization. ISBN   978-92-2-109817-1.
  7. Sax, N.Irving; Bruce, Robert D (1989). Dangerous properties of industrial materials. Vol. 3 (7th ed.). John Wiley & Sons. ISBN   0-442-27368-1.
  8. Meyer, Rudolf; Köhler, Josef; Homburg, Axel (2016). Explosives. John Wiley & Sons. ISBN   978-3-527-68961-3.
  9. 1 2 "2,4-Dinitrophenol" (PDF). Environmental Protection Agency . Retrieved 15 October 2017.
  10. Gupta, Ramesh C., ed. (2011). Reproductive and developmental toxicology. London: Academic Press. p. 509. ISBN   978-0-12-382032-7. OCLC   717387050.
  11. Pohanish, Richard P. (2011). Sittig's Handbook of Toxic and Hazardous Chemicals and Carcinogens. William Andrew. ISBN   978-1-4377-7870-0.
  12. "Toxicological Profile for Dinitrophenols" (PDF). Agency for Toxic Substances and Disease Registry. U.S. Department of Health and Human Services. August 2021.
  13. Pohanish, Richard P. (2014). Sittig's Handbook of Pesticides and Agricultural Chemicals. William Andrew. ISBN   978-1-4557-3157-2.
  14. "Q. Dinitrophenol". www.parallelparliament.co.uk. Retrieved 7 February 2023.
  15. Agrawal, Jai Prakash; Hodgson, Robert (2007). Organic Chemistry of Explosives. John Wiley & Sons. ISBN   978-0-470-05935-7.
  16. 1 2 3 4 5 6 7 Bateman, Nick; Jefferson, Robert; Thomas, Simon; Thompson, John; Vale, Allister (2014). "Dinitrophenol". Oxford Desk Reference: Toxicology. Oxford University Press. pp. 258–259. ISBN   978-0-19-102248-7.
  17. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Grundlingh, Johann; Dargan, Paul I.; El-Zanfaly, Marwa; Wood, David M. (1 September 2011). "2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death". Journal of Medical Toxicology. 7 (3): 205–212. doi: 10.1007/s13181-011-0162-6 . ISSN   1937-6995. PMC   3550200 . PMID   21739343.
  18. Urben, Peter (2017). Bretherick's Handbook of Reactive Chemical Hazards. Elsevier. ISBN   978-0-08-101059-4.
  19. "Commerce in Explosives; 2017 Annual List of Explosive Materials". Federal Register. 28 December 2017. Retrieved 22 July 2018.
  20. 1 2 Abdelati, Ali; Burns, Michele M.; Chary, Michael (2023). "Sublethal toxicities of 2,4-dinitrophenol as inferred from online self-reports". PLOS ONE. 18 (9): e0290630. Bibcode:2023PLoSO..1890630A. doi: 10.1371/journal.pone.0290630 . ISSN   1932-6203. PMC   10499234 . PMID   37703241.
  21. Christoffersen, Berit Østergaard; Sanchez-Delgado, Guillermo; John, Linu Mary; Ryan, Donna H.; Raun, Kirsten; Ravussin, Eric (April 2022). "Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss". Obesity. 30 (4): 841–857. doi:10.1002/oby.23374. ISSN   1930-7381. PMC   9310705 . PMID   35333444.
  22. Ost, Mario; Keipert, Susanne; Klaus, Susanne (March 2017). "Targeted mitochondrial uncoupling beyond UCP1 – The fine line between death and metabolic health". Biochimie. 134: 77–85. doi:10.1016/j.biochi.2016.11.013. PMID   27916644. S2CID   6867183.
  23. 1 2 Meyer, Lyndsey F.; Rajadhyaksha, Pooja M.; Shah, Dhaval K. (1 June 2022). "Physiologically-based pharmacokinetic model for 2,4-dinitrophenol". Journal of Pharmacokinetics and Pharmacodynamics. 49 (3): 325–336. doi:10.1007/s10928-022-09806-y. ISSN   1573-8744. PMID   35089483. S2CID   246361178.
  24. Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041. PMID   37059159. S2CID   258115543.
  25. 1 2 3 4 5 6 7 8 Petróczi, Andrea; Ocampo, Jorge A. Vela; Shah, Iltaf; Jenkinson, Carl; New, Rachael; James, Ricky A.; Taylor, Glenn; Naughton, Declan P. (14 October 2015). "Russian roulette with unlicensed fat-burner drug 2,4-dinitrophenol (DNP): evidence from a multidisciplinary study of the internet, bodybuilding supplements and DNP users". Substance Abuse Treatment, Prevention, and Policy. 10 (1): 39. doi: 10.1186/s13011-015-0034-1 . ISSN   1747-597X. PMC   4607104 . PMID   26466580.
  26. McVeigh, Jim; Germain, Jennifer; Van Hout, Marie Claire (2017). "2,4-Dinitrophenol, the inferno drug: a netnographic study of user experiences in the quest for leanness" (PDF). Journal of Substance Use. 22 (2): 131–138. doi:10.3109/14659891.2016.1149238. S2CID   147770507.
  27. 1 2 3 Gziut, Tomasz; Thomas, Simon H. L. (23 November 2021). "International trends in systemic human exposures to 2,4 dinitrophenol reported to poisons centres". Clinical Toxicology. 60 (5): 628–631. doi: 10.1080/15563650.2021.2005797 . ISSN   1556-3650. PMID   34812657. S2CID   244490656.
  28. Weiss, Roy E.; Refetoff, Samuel (2016). "Chapter 78 - Thyroid Function Testing". Endocrinology: Adult and Pediatric (Seventh ed.). W.B. Saunders. p. 1397. ISBN   978-0-323-18907-1.
  29. Richard, Thomas; Weidhaas, Jennifer (15 September 2014). "Biodegradation of IMX-101 explosive formulation constituents: 2,4-Dinitroanisole (DNAN), 3-nitro-1,2,4-triazol-5-one (NTO), and nitroguanidine". Journal of Hazardous Materials. 280: 372–379. doi:10.1016/j.jhazmat.2014.08.019. ISSN   0304-3894. PMID   25181681.
  30. Chen, Lili; Cheng, Zihan; Peng, Xinyue; Qiu, Guoqiao; Wang, Li (2022). "Eu-Doped MOF-based high-efficiency fluorescent sensor for detecting 2,4-dinitrophenol and 2,4,6-trinitrophenol simultaneously". Analytical Methods. 14 (1): 44–51. doi:10.1039/D1AY01747K. PMID   34889337. S2CID   244787652.
  31. Feng, Hai-Tao; Zheng, Yan-Song (3 January 2014). "Highly Sensitive and Selective Detection of Nitrophenolic Explosives by Using Nanospheres of a Tetraphenylethylene Macrocycle Displaying Aggregation-Induced Emission". Chemistry - A European Journal. 20 (1): 195–201. doi:10.1002/chem.201302638. PMID   24285612.
  32. Adegoke, Oluwasesan; Daeid, Niamh Nic (October 2021). "Polymeric-coated Fe-doped ceria/gold hybrid nanocomposite as an aptasensor for the catalytic enhanced colorimetric detection of 2,4-dinitrophenol". Colloids and Surfaces A: Physicochemical and Engineering Aspects. 627: 127194. doi:10.1016/j.colsurfa.2021.127194. S2CID   237672987.
  33. Dinesh, Bose; Aadhav, Anantharamakrishnan; Devi, K. S. Shalini; Krishnan, Uma Maheswari (1 June 2022). "Electrocatalytic reduction of 2,4 dinitrophenol on carbon black-modified glassy carbon electrode and its selective recognition in cold beverages". Carbon Letters. 32 (4): 1017–1029. doi:10.1007/s42823-022-00334-w. ISSN   2233-4998. S2CID   247942852.
  34. Xu, Zhuang; Wen, Yuquan; Tian, Li; Li, Guangtao (March 2017). "Efficient and selective adsorption of nitroaromatic explosives by Zr-MOF". Inorganic Chemistry Communications. 77: 11–13. doi:10.1016/j.inoche.2017.01.025.
  35. 1 2 3 4 5 Yen, May; Ewald, Michele Burns (2012). "Toxicity of Weight Loss Agents". Journal of Medical Toxicology. 8 (2): 145–152. doi: 10.1007/s13181-012-0213-7 . ISSN   1937-6995. PMC   3550246 . PMID   22351299.
  36. Zack, F.; Gummesson, A.; Büttner, A. (1 October 2022). "Morphologische Befunde als Hinweise auf eine 2,4-Dinitrophenol-Intoxikation". Rechtsmedizin (in German). 32 (5): 386–390. doi:10.1007/s00194-021-00552-y. ISSN   1434-5196. S2CID   245336193.
  37. Potts, A. J.; Bowman, N. J.; Seger, D. L.; Thomas, S. H. L. (3 June 2021). "Toxicoepidemiology and predictors of death in 2,4-dinitrophenol (DNP) toxicity". Clinical Toxicology. 59 (6): 515–520. doi:10.1080/15563650.2020.1826505. PMID   33021407. S2CID   222159746.
  38. 1 2 3 4 5 6 7 8 9 Colman, Eric (2007). "Dinitrophenol and obesity: An early twentieth-century regulatory dilemma". Regulatory Toxicology and Pharmacology. 48 (2): 115–117. doi:10.1016/j.yrtph.2007.03.006. PMID   17475379.
  39. 1 2 3 Swann, John P. (2010). "Reducing with dinitrophenol : self-medication, and the challenge of regulating a dangerous pharmaceutical before the US Food, Drug, and Cosmetic Act". Perspectives on Twentieth-century Pharmaceuticals. Peter Lang. pp. 289, 292, 299, 301. ISBN   978-3-03910-920-3.
  40. 1 2 Casey, Scott (10 December 2019). "2,4-Dinitrophenol – effective but dangerous fat burner". Australian Pharmacist. Retrieved 17 September 2023.
  41. Hippensteele, Alana (7 May 2021). "Pharmacy Fact: Miracle Weight Loss Drug Successfully Burns Fat, Also 'Cooks' Internal Organs". Pharmacy Times. Retrieved 17 September 2023.
  42. Wickware, Carolyn (27 January 2023). "Government to change law to reclassify so-called 'diet drug' as a poison". The Pharmaceutical Journal. Retrieved 29 January 2023.
  43. Anvisa (24 July 2023). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 25 July 2023). Archived from the original on 27 August 2023. Retrieved 27 August 2023.
  44. Geisler, John G. (23 March 2019). "2,4 Dinitrophenol as Medicine". Cells. 8 (3): 280. doi: 10.3390/cells8030280 . ISSN   2073-4409. PMC   6468406 . PMID   30909602.
  45. "DNP: Is it really all that dangerous?". opss. Retrieved 18 September 2023.
  46. "Eloise Parry: Man convicted over diet pill death". BBC News. 9 March 2020.

Further reading